Tradestie Institutional Equity Comparison Engine
VIVS vs SLS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SLS Overall Edge
SLS Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SELLAS Life Sciences Group, Inc. Common Stock (SLS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus SLS at N/M Forward P/E and 0.0% operating margin (-82.5% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against SLS sits in CONSOLIDATION (16th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VIVS N/M vs SLS N/M Fwd P/E
Growth & Margin Winner
SLS
Op Margin -10117.0% vs 0.0% ยท YoY -51.4% vs -82.5%
Momentum & Technical Winner
SLS
1Y -87.0% vs +834.6% ยท 52W Pos 5% vs 57%
Options & Structure Winner
SLS
BREAKDOWN (N/A IV) vs CONSOLIDATION (16th %ile IV)
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
SLS
NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$14.86
-17.21% 1D
Market Cap
$3.7B
1M Return
+22.41%
1Y Return
+834.59%
Forward P/E
N/M
Unified AI Score
39.3 / 100
SELL
Tech 50.0
Fund 37.0
Flow 68.0
Mom 48.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VIVS -86.99%
SLS +834.59%
Spread: +921.58 pp (SLS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VIVS Revenue | SLS Revenue | VIVS Op. Margin | SLS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -882.4% | N/A | VIVS |
| FY2020 | $0M | $0M | -977.9% | -893.8% | SLS |
| FY2021 | N/A | $10M | N/A | -332.8% | SLS |
| FY2022 | $0M | $0M | -765.3% | -4195.0% | VIVS |
| FY2023 | $0M | N/A | -4792.2% | N/A | VIVS |
| FY2024 | $0M | N/A | -13840.4% | N/A | VIVS |
| FY2025 | $0M | N/A | -8761.1% | N/A | VIVS |
| FY2026 | $0M | N/A | -8768.7% | N/A | VIVS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VIVS | SLS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.4M | $3.7B | Larger Scale | SLS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -51.4% | -82.5% | Higher Growth | VIVS |
| Operating Margin (TTM) Profitability | -10117.0% | 0.0% | Higher Margin | SLS |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -343.1% | -40.3% | Higher ROE | SLS |
| 52-Week Range Position Momentum | 5% ($0โ$3) | 57% ($1โ$25) | Stronger Trend | SLS |
| Beta / 30D Volatility Risk Regime | 0.83ฮฒ ยท 480% Vol | 1.84ฮฒ ยท 551% Vol | Lower Realized Risk | VIVS |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 39.3 / 100 (SELL) | Higher Composite | SLS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VIVS vs SLS Buy Guide
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SLS
CONSOLIDATION
101d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VIVS nor SLS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.